Pfizer’s RSV vaccine shows benefit in immuno-compromised adults in study Investing.com Pfizer’s RSV vaccine shows benefit in immuno-compromised adults in study. Pfizer (PFE) 1 month
3 Magnificent Dividend Stocks With Yields Above 5% to Buy Now and Hold Forever The Motley Fool 22 hours
Pfizer says drug for deadly cancer condition that causes weight loss shows positive trial data CNBC 5 days
The Brawl Taking Shape Over Pfizer’s Multibillion-Dollar Heart Monopoly The Wall Street Journal 7 days
Pfizer Inc. (PFE) Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript) Seeking Alpha 2 weeks
Vaxcyte Catapults As It Looks To Take On Pfizer, Merck In A Massive Market Investor's Business Daily 2 weeks
Pfizer. Inc. (PFE): One of the Best Affordable Stocks Under $40 According to Short Sellers Insider Monkey 3 weeks
Pfizer: Look Beyond COVID-19 And The Patent Cliffs – Robust Long-Term Tailwinds Seeking Alpha 3 weeks
Why IBD 50’s Alnylam Just Reversed Its 50% Gain — And BridgeBio Surged Investor's Business Daily 3 weeks
The forgotten pharma stocks left in the dust by Eli-Lilly could be primed for a comeback CNBC 3 weeks
Want $2,000 in Annual Dividends? Invest $30,000 in These 3 High-Yielding Stocks The Motley Fool 4 weeks
FDA approves new updated COVID-19 vaccines to target KP.2 variant. Here’s what to know Fast Company 4 weeks
Looking for $1500 in Safe Passive Income Each Year? Invest This Much in Pfizer. 24/7 Wall St. 4 weeks
Pfizer Slides Toward Sell Zone After BioNTech-Tied Covid/Flu Shot Misses Its Mark Investor's Business Daily 1 month
Pfizer-BioNTech’s COVID-19-and-flu combination drug meets 1 of 2 trial objectives MarketWatch 1 month
Prediction: This Company Will Disrupt Eli Lilly and Novo Nordisk in the Weight Loss Market (Hint: It’s Not Pfizer) The Motley Fool 1 month
Pfizer reports positive results in study of vaccine for immunocompromised adults at risk of severe RSV-related illness MarketWatch 1 month